

Dan,


Thank you for your November 27, 2004 e-mail in which you provided your thoughts on the perception of the prescription pharmaceutical industry and AstraZeneca and raised certain issues relating to AstraZeneca's promotion of SEROQUEL® (quetiapine fumarate). I apologize for the delay in responding.

AstraZeneca is committed to conducting business with the highest ethical standards and in full compliance with the laws and regulations governing our industry. Consistent with this Company focus on compliance, AstraZeneca is absolutely committed to only promoting its products for approved uses. There are a variety of initiatives underway throughout the Company to ensure that this occurs. For instance, the Legal Department in 2004 prepared a comprehensive document on Off-Label Information – General Principles and shared this document with a variety of senior leaders in the organization, who have in turn cascaded the Company's policies and expectations. Company attorneys are conducting training for a variety of groups on off-label information, including the SEROQUEL team. Compliance, including the appropriate promotion of SEROQUEL, is an important element of the upcoming Business Emphasis Meetings. The Compliance, Legal and Human Resources functions continue to actively investigate allegations of off-label promotion and other policy violations.

You raised the issue of AstraZeneca Long Term Care (LTC) PSSs calling on psychiatrists in LTC, some of whom write SEROQUEL off-label for the treatment of agitation in demented patients. As you may be aware, a significant focus of the SEROQUEL Brand Team in 2004 was ensuring the appropriate promotion of SEROQUEL in LTC. AstraZeneca has refocused its targeting in LTC to ensure that we maximize the potential for scripts being written for the two approved indications of schizophrenia and bipolar mania. We have reduced the frequency of calls on facilities and/or customers where the percentage of on-label scripts is known to be low. Additionally, AstraZeneca Sales and Legal leadership provided training on policy and targeting to the LTC sales force to ensure the continued appropriate promotion of SEROQUEL in LTC.

You also raised the issue of PSSs calling on child and adolescent psychiatrists, some of whom write SEROQUEL off-label for patients below the age of 18. This too is an issue that the SEROQUEL team is aware of and continues to monitor. SEROQUEL is of course not approved for pediatrics and cannot be promoted for use in this patient population. However, the SEROQUEL team has confirmed that child and adolescent psychiatrists treat a significant percentage of patients (approximately 40%) over the age of 18. Accordingly, the team has determined that it continues to be appropriate to have PSSs call on these physicians, directing their efforts to the use of SEROQUEL in adult patients only.

Although you acknowledged in your e-mail that "some of these issues have now been addressed", you raised questions as to AstraZeneca's motivation in addressing these issues. Please appreciate that, to the extent that AstraZeneca has made any changes in its



promotional practices or targeting relating to SEROQUEL, these changes were not motivated by lawsuits or investigations brought against competitors. Rather they were motivated by AstraZeneca's ongoing commitment to compliance and to ensuring that we promote our products in a manner that is both compliant and best for the business. AstraZeneca is the type of company that takes the lead in compliance, not a company that simply reacts to legal and regulatory actions against competitors.

You also stated in your e-mail that you "can cite other examples of current situations that I believe do not fit our stated business ethics." As was made clear in the recent compliance training, all employees have an affirmative duty to disclose any perceived policy violations or ethical concerns. If you have specific concerns, please raise them promptly with your management, the Ethics Helpline or me. Alternatively, I invite you to discuss any concerns you have with Steve Mohr, Deputy Compliance Officer, and/or Jeff Fleming, the AstraZeneca attorney who currently supports the SEROQUEL Team. We will follow up on the issues and take appropriate action.

Thanks again for communicating your perspective and concerns, and for your contributions to AstraZeneca.